Literature DB >> 10698467

Comparison of counter immunoelectrophoresis with immunoblotting for detection of anti-extractable nuclear antigen antibodies in systemic lupus erythematosus.

E Y Chan1, T M Mok, J W Lawton, O K Ko, L Ho, C S Lau.   

Abstract

Anti-extractable nuclear antigen (ENA) antibodies were assayed by counter immunoelectrophoresis (CIE) and immunoblotting in patients with systemic lupus erythematosus (SLE). We found the two methods showed good concordance rates, the lowest being 67% for anti-SS-A. Immunoblotting was more sensitive in detecting anti-Sm, anti-SS-B and anti-PCNA (proliferating cell nuclear antigen); CIE was more sensitive for anti-nRNP and anti-SS-A. Overall, the prevalence of these anti-ENA antibodies in SLE was increased by 9-20% if immunoblotting was used in addition to CIE. Sera specific for the 52 kDa peptide of the SS-A antigen (anti-52kDa SS-A) were better detected by immunoblotting. Anti-PCNA antibody was found in 6.3% of SLE patients and was associated with active disease and hemolytic anemia. The positive rate of anti-Sm was 9% by CIE and 23.7% by immunoblotting and this antibody was a specific marker for SLE using either method. It was concluded that using immunoblotting in addition to CIE, the overall sensitivity of detection of anti-ENA antibodies in SLE was increased and clinically useful antibodies such as anti-52kDa SS-A and anti-PCNA could be detected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10698467

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  2 in total

1.  Clinical aspects and risk factors of lupus nephritis: a retrospective study of 156 adult patients.

Authors:  Fang Yuan; Fenghua Wei; Junjie Wang; Yanwu You
Journal:  J Int Med Res       Date:  2019-09-12       Impact factor: 1.671

2.  The Predictive Value of Autoantibody Spectrum on Organ Damage in Patients With Systemic Lupus Erythematosus.

Authors:  Fang Yuan; Fenghua Wei; Haiting Huang; Yi Xue; Pengwei Guo; Yanwu You
Journal:  Arch Rheumatol       Date:  2018-08-16       Impact factor: 1.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.